ConSynance wins FDA designation for Prader-Willi syndrome therapy
The US Food and Drug Administration (FDA) has granted ConSynance Therapeutics a rare paediatric disease designation for its oral therapy…
The US Food and Drug Administration (FDA) has granted ConSynance Therapeutics a rare paediatric disease designation for its oral therapy…
As increasing varieties of drugs aimed at weight loss hit the shelves, a new treatment that targets obesity and hunger…
Shionogi has concluded an exclusive global licence agreement for Maze Therapeutics’s MZE001, an oral glycogen synthase 1 (GYS1) inhibitor to…
Zydus Lifesciences subsidiary Sentynl Therapeutics has announced the worldwide acquisition of the Zokinvy (lonafarnib) programme from Eiger BioPharmaceuticals for the…
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved TMC Pharma's fosdenopterin (Nulibry) for the treatment of molybdenum…
Biotechnology company Diagonal Therapeutics has announced its launch, raising $128m through a Series A financing round for its new approach…
The US Food and Drug Administration (FDA) has granted approval to Orchard Therapeutics' Lenmeldy (atidarsagene autotemcel) gene therapy for use…
Sionna Therapeutics has continued raising capital, closing a $182m Series C financing round to help advance additional cystic fibrosis candidates…
The US Food and Drug Administration (FDA) has granted orphan drug designation to Ionis Pharmaceuticals’ olezarsen, an investigational ligand conjugated…
Kyowa Kirin, a Japan-based global speciality pharmaceutical company, has announced the successful completion of its acquisition of Orchard Therapeutics, a…